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Abstract 
Human hepatocytes cultured in a monolayer configuration represent a well-established in 
vitro model in liver toxicology, notably used in drug transporter studies. Polarized status of 
drug transporters, i.e., their coordinated location at sinusoidal or canalicular membranes, 
remains however incompletely documented in these cultured hepatocytes. The present study 
was therefore designed to analyze transporter expression and location in such cells. Most of 
drug transporters were first shown to be present at notable mRNA levels in monolayer-
cultured human hepatocytes. Cultured human hepatocytes, which morphologically exhibited 
bile canaliculi-like structures, were next demonstrated, through immunofluorescence staining, 
to express the influx transporters organic anion transporting polypeptide (OATP) 1B1, 
OATP2B1 and organic cation transporter (OCT) 1 and the efflux transporter multidrug 
resistance-associated protein (MRP) 3 at their sinusoidal pole. In addition, the efflux 
transporters P-glycoprotein and MRP2 were detected at the canalicular pole of monolayer-
cultured human hepatocytes. Moreover, canalicular secretion of reference substrates for the 
efflux transporters bile salt export pump, MRP2 and P-glycoprotein as well as sinusoidal drug 
transporter activities were observed. This polarized and functional expression of drug 
transporters in monolayer-cultured human hepatocytes highlights the interest of using this 
human in vitro cell model in xenobiotic transport studies. 
 
Key-words: Canalicular secretion, Drug transporter, Hepatocytes, Polarization, Primary 
culture.  
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1. Introduction 
 Liver transporters, belonging either to the solute carrier (SLC) transporter family or to 
the ATP-binding cassette (ABC) transporter family, are now well-recognized as major actors 
of hepatic drug clearance (Giacomini et al., 2010). Indeed, they are expressed either at the 
sinusoidal pole of hepatocytes, where they mediate uptake of drugs from blood into 
hepatocytes, i.e., the so-called phase 0 of the hepatic detoxifying system, or at the canalicular 
pole of hepatocytes, where they secrete drugs or drug metabolites into the bile, i.e., the so-
called phase 3a of the hepatic detoxifying system (Funk, 2008). Additionally, some sinusoidal 
ABC transporters can secrete drug metabolites back into the blood, i.e., the so-called phase 
3b, for a secondary renal elimination (Pfeifer et al., 2014).  
 Activity of hepatic transporters as well as their expression can be regulated by various 
drugs (Jigorel et al., 2006; Klaassen and Aleksunes, 2010), which can result in clinically-
significant drug-drug interactions through altered hepatic elimination of the co-administrated 
drugs handled by the targeted transporters (Konig et al., 2013). Other xenobiotics such as 
environmental pollutants and some physiological factors, including hormones and 
inflammatory cytokines, can also impair hepatic drug transporter expression and activity 
(Fardel and Le Vee, 2009; Fardel et al., 2001; Klaassen and Slitt, 2005). Identifying putative 
interactions of drugs, chemical pollutants or endogenous substances with hepatic drug 
transporters and characterizing the cellular and molecular mechanisms involved in such 
interactions are therefore likely important issues that have to be addressed, notably during the 
development of new molecular entities in pharmaceutical companies, as recently 
recommended by drug regulatory agencies (Giacomini and Huang, 2013; Prueksaritanont et 
al., 2013).  
 For performing such studies on hepatic drug transporter activity and expression, 
primary cultures of hepatocytes represent an in vitro choice model (Brouwer et al., 2013; 
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Ramboer et al., 2013). For rodent hepatocytes, such cultures are usually performed under a 
sandwich configuration, i.e., hepatocytes are plated on collagen-coated dishes and overlaid 
with collagen or matrigel (LeCluyse et al., 1994), which permits to recover a polarized status 
of hepatocytes and functional bile canaliculi networks (Swift et al., 2010). By contrast, rodent 
hepatocytes cultivated in a conventional monolayer configuration, i.e., hepatocytes are plated 
on plastic or collagen-coated dishes, failed to exhibit bile canaliculi-like structures and are 
therefore not convenient for studying canalicular drug secretion (Luttringer et al., 2002; Noel 
et al., 2013). In analogy to sandwich-cultured rodent hepatocytes, sandwich-cultured human 
hepatocytes are thought to represent the gold standard for in vitro investigating human hepatic 
transporters (Bi et al., 2012; De Bruyn et al., 2013).  It is however noteworthy that monolayer-
cultured human hepatocytes also display notable activity of various drug transporters (Jigorel 
et al., 2005; Payen et al., 2000) and that absolute quantification of sinusoidal and canalicular 
transporters through a targeted liquid chromatography coupled to tandem mass spectrometry 
(LC-MS/MS) method revealed no major difference between sandwich- and monolayer-
cultured human hepatocytes  (Schaefer et al., 2012). Moreover, primary human hepatocytes 
cultivated in a monolayer configuration retain regulatory ways of transporter expression and 
have been consequently used for analyzing the effects of drugs or physiological effectors such 
as cytokines or growth factors on drug transporter levels and activities (Jigorel et al., 2006; Le 
Vee et al., 2008; Le Vee et al., 2009a; Richert et al., 2009). Whether such monolayer-cultured 
human hepatocytes exhibit polarized expression of drug transporters, and therefore may 
closely mimic the in vivo situation, remains however yet largely unknown, but is rather 
important to determine in order to fully assess the relevance of monolayer-cultured human 
hepatocytes as a valuable in vitro model to investigate hepatic drug transport. The present 
study was therefore designed to get insights about this point, using a combined experimental 
approach, based on mRNA quantification, immunofluorescence labeling and canalicular 
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transport assays, and very similar to that  recently used for characterizing drug transporter 
location in highly differentiated human hepatoma HepaRG cells (Le Vee et al., 2013).  
 
 
2. Materials and methods 
2.1 Chemicals  
 Rhodamine 123, verapamil and probenecid were purchased from Sigma-Aldrich 
(Saint-Quentin Fallavier, France), whereas carboxy-2,7-dichlorofluoresceine (CF) diacetate 
was provided by Invitrogen/Life Technologies (Villebon sur Yvette, France). [3H(G)] 
taurocholic acid (sp. act. 1.19 Ci/mmol), [6,7-3H(N)] estrone-3-sulfate (E3S) (sp. act. 57.3 
Ci/mmol) and [1-14C] tetra-ethylammonium (TEA) (sp. act. 2.4 mCi/mmol) were from 
Perkin-Elmer (Boston, MA). All other chemicals were commercial products of the highest 
purity available. 
 
2.2 Cell culture  
 Human hepatocytes were obtained from adult donors undergoing hepatic resection for 
primary and secondary tumors or other pathologies, via the Biological Resource Center 
(University Hospital, Rennes, France). Cells were prepared by enzymatic dissociation of 
histologically-normal liver fragments (Fardel et al., 1993). These freshly isolated hepatocytes 
were either immediately collected for further RNA isolation and analysis or were seeded on 
standard tissue-culture plastic plates (BD Biosciences, Le Pont de Claix, France) at a density 
of approximately 2 × 105 cells/cm2 in Williams' E medium (Invitrogen, Cergy-Pontoise, 
France), supplemented with 10% fetal calf serum (Perbio Sciences, Brébieres, France), 5 
µg/ml bovine insulin (Sigma-Aldrich), 100 IU/ml penicillin, 100 µg/ml streptomycin, and 2 
mM glutamine (Invitrogen). After 24 h, this seeding medium was discarded, and hepatocytes 
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were cultured in the fetal calf serum-containing Williams' E medium defined above and 
supplemented with 5 × 10−5 M hydrocortisone hemisuccinate (Upjohn, Paris La Défense, 
France) and 2% dimethyl sulfoxide (DMSO), as reported previously (Chouteau et al., 2001; 
Le Vee et al., 2009b), knowing that DMSO is well-known to promote differentiation and 
survival of hepatocytes (Isom et al., 1985). The culture medium was routinely renewed every 
2 days. All experimental procedures complied with French laws and regulations and were 
approved by the National Ethics Committee. Hepatocytes usually form nearly-confluent 
monolayers of viable cells and were used for experiments after a 8-10 days culture period. 
 
2.3 RNA isolation and analysis  
 Total RNA was isolated from freshly isolated and monolayer-cultured human 
hepatocytes using the TRIzol reagent (Invitrogen/Life Technologies). RNA (20 ng) was then 
subjected to reverse transcription-quantitative polymerase chain reaction (RT-qPCR), using 
the fluorescent dye SYBR Green methodology and an ABI Prism 7300 detector (Applied 
Biosystem, Foster City, CA, USA), as previously described (Le Vee et al., 2013).The gene 
primers used in the study were exactly as previously reported (Le Vee et al., 2013; Moreau et 
al., 2011); their adequate efficiency was routinely checked using serially diluted RNA 
samples. Amplification curves of the PCR products were analyzed with the ABI Prism SDS 
software using the comparative cycle threshold (Ct) method. Relative quantification of the 
steady-state target mRNA levels for transporters was next calculated after normalization of 
the total amount of cDNA tested to an 18S RNA endogenous reference, knowing that the 
amount of 18S RNA in freshly isolated human and monolayer-cultured human hepatocytes 
was found to be constant, i.e., the Ct numbers determined from qPCR assays were similar in 
these cells (Fig. S1), and was arbitrarily set at 106 units in each PCR sample (Moreau et al., 
  
7 
 
2011). This finally allowed to get a relative value of expression for each transporter 
comparatively to the 18S RNA reference.  
 
2.4 Light microscopy analysis 
 Light microscopy analysis of monolayer cultures of  human hepatocytes was 
performed using an Axiovert microscope (Carl Zeiss, Le Pecq, France), as previously 
described (Le Vee et al., 2013).  
 
2.5 Immunolocalization studies 
 Immunofluorescence analyses were performed as previously reported (Le Vee et al., 
2009b; Le Vee et al., 2013). Human hepatocytes, cultured on glass coverslips (Millicell EZ 
slides, Merck Millipore, Billerica, MA) for 8-10 days at the density of approximately 2 × 
105 cells/cm2 in the medium described above, were first fixed in ice-cold acetone for 10 min. 
Cells were next incubated for 3 h with mouse monoclonal or rabbit polyclonal antibodies 
diluted to 1:50 (mouse antibodies) or 1:25 (rabbit antibodies) in phosphate-buffered saline 
supplemented with 4 % (weight/weight) bovine serum albumin. The mouse monoclonal 
antibodies were directed against organic cation transporter 1 (OCT1)/SLC22A1 (Abcam, 
Cambridge, UK), multidrug resistance gene 1 (MDR1)/ABCB1/P-glycoprotein (Alexis 
Corporation, Lausen, Switzerland), multidrug drug resistance-associated protein (MRP) 
2/ABCC2 or MRP3/ABCC3 (Merck Millipore), whereas the rabbit polyclonal antibodies 
were raised against organic anion transporting polypeptide (OATP) 1B1/SLCO1B1 or 
OATP2B1/SLCO2B1 (Huber et al., 2007). Controls were performed in parallel with 
appropriate mouse or rabbit isotypic Ig controls. After washing, goat AlexaFluor 488-labeled 
secondary antibodies (Invitrogen/Life Technologies) were added for 1 h, and nuclei were 
subsequently stained with 4,6-diamidino-2-phenylindole. Immunofluorescence images were 
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finally detected with a Zeiss Axioskop A1 microscope (Carl Zeiss) and a Nikon DS-2MBW 
camera (Nikon, Champigny-sur-Marne, France), using the NIS-Elements F3.2 software 
(Nikon).  
 
2.6 Drug transport assays  
 2.6.1 Sinusoidal influx assay 
 Uptake transport activities due to the sinusoidal transporters sodium-taurocholate 
cotransporting polypeptide (NTCP/SLC10A1), OATPs and OCT1 were analyzed through 
measuring  sodium-dependent-intracellular accumulation of the NTCP substrate taurocholate, 
probenecid-sensitive uptake of the OATP substrate E3S and verapamil-sensitive uptake of the 
OCT1 substrate TEA, using a defined transport assay medium consisting of 5.3 mM KCl, 1.1 
mM KH2PO4, 0.8 mM MgSO4, 1.8 mM CaCl2, 11 mM d-glucose, 10 mM HEPES, and 136 
mM N-methyl glucamine (sodium-free buffer) or 136 mM NaCl (standard sodium-containing 
buffer), as previously described (Noel et al., 2013). Briefly, cells were incubated at 37 °C for 
10 min in the transport medium supplemented with 43.4 nM [3H] taurocholate in the presence 
or absence of sodium, 3.4 nM [3H] E3S in the presence or absence of the OATP inhibitor 
probenecid (2 mM) or 40 µM [14C] TEA in the presence or absence of the OCT1 inhibitor 
verapamil (50 µM). After washing in phosphate-buffered saline, cells were lyzed and 
accumulation of radiolabeled substrates was determined through scintillation counting. 
Taurocholate accumulation values in the presence of sodium minus accumulation values in 
the absence of sodium, E3S uptake values in the absence of probenecid minus uptake values 
in the presence of probenecid and TEA uptake values in the absence of verapamil minus 
uptake values in the presence of verapamil are thought to represent NTCP-, OATPs- and 
OCT1-related transport activities (Jigorel et al., 2005).  
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 2.6.2 Canalicular secretion assay 
 Biliary secretion of taurocholate, CF and rhodamine 123 was determined through 
measurement of radiolabeled or fluorescent substrate accumulation into bile canaliculi-like 
structures, as previously reported (Annaert et al., 2001; Le Vee et al., 2013). Briefly, 
monolayer-cultured human hepatocytes were first incubated for 10 min at 37°C with the 
defined Ca2+-containing transport assay buffer described aboved or with the same buffer, 
except that 1.8 mM CaCl2 was withdrawed and 100 µM EGTA was added; such an incubation 
in  this Ca2+-free buffer is known to promote disruption of tight junctions and opening of bile 
canaliculi networks. Buffers were then removed and cultured human hepatocytes cells were 
further incubated for 10 min at 37°C in transport assay medium containing 43.4 nM [3H] 
taurocholate, 3 µM CF diacetate or 5.25 µM rhodamine 123. After washing with ice-cold 
phosphate-buffered saline, accumulations of taurocholate, CF or rhodamine 123 into cells + 
bile canaliculi (Ca2+-containing conditions) and into cells only (Ca2+-free conditions) were 
determined by scintillation counting (for taurocholate) or spectrofluorimetry (for CF and 
rhodamine 123) using a SpectraMax Gemini SX spectrofluorometer (Molecular Devices, 
Sunnyvale, CA) (excitation and emission wavelengths were 485 and 535 nm, respectively). 
Biliary excretion index (BEI) was finally calculated using the following equation (Liu et al., 
1999a): 
 
2.7 Statistical analysis. Quantitative data were analyzed using the two-sided Student’s t-test. 
The criterion of significance was p < 0.05.   
 
 
Accumulation (Cells+Bile canaliculi)
BEI= 
Accumulation (Cells+Bile canaliculi) – Accumulation (Cells)
X 100
  
10 
 
3. Results 
 Relative mRNA expressions of SLC and ABC drug transporters in monolayer-cultured 
human hepatocytes and freshly isolated human hepatocytes were first quantified by RT-
qPCR. As shown in Fig. 1, expressions of the sinusoidal SLC transporters NTCP and OCT1 
as well as those of the sinusoidal ABC efflux transporters MRP1 and MRP3 were similar and 
not statistically different in both cultured human hepatocytes and freshly isolated human 
hepatocytes. By contrast, mRNA expressions of the sinusoidal SLC transporters OATP1B1, 
OATP2B1, organic anion transporter 2 (OAT2/SLC22A7) and, in a more marked manner, 
OATP1B3 (SLCO1B3), were reduced in cultured human hepatocytes when compared to 
freshly isolated hepatocytes; the repression factors, i.e., the ratio mRNA levels in freshly 
isolated hepatocytes versus those in primary counterparts, range for these transporters from 
1.8 (for OATP2B1) to 22.2 (for OATP1B3). Expressions of the sinusoidal efflux transporters 
MRP4 (ABCC4), MRP5 (ABCC5) and MRP6 (ABCC6) were found to be induced in 
monolayer-cultured human hepatocytes (Fig. 1), knowing that MRP4 and MRP5, in contrast 
to MRP6, remain rather poorly expressed in monolayer-cultured hepatocytes (expression < 1 
arbitrary unit for MRP4 and MRP5 versus expression = 177.5 arbitrary units for MRP6). With 
respect to canalicular transporters (Fig. 2), MDR1 and MRP2 mRNA levels were up-regulated 
in cultured human hepatocytes when compared to freshly isolated hepatocytes, whereas those 
of bile salt export pump (BSEP/ABCB11) and breast cancer resistance protein 
(BCRP/ABCG2) were reduced and those of multidrug and toxin extrusion 1 transporter 
(MATE1/SLC47A1) unchanged.   
 To schematically categorize drug transporter expression in freshly isolated human 
hepatocytes and in monolayer-cultured counterparts, transporters were next classified 
according to their level of mRNA expression: low expression (<1 unit), moderate expression 
(1-15 units), high expression (15-100 units) and very high expression (>100 units) (Table 1). 
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Most of drug transporters were ranged into the same expression level category in both freshly 
isolated human hepatocytes and monolayer-cultured counterparts (Table 1). In particular, 
OCT1 exhibited a very high expression, whereas MRP1, MRP4 and MRP5 were among the 
less expressed.  
 Light-microscopic analysis of hepatocyte cultures next demonstrated that monolayer-
cultured human hepatocytes exhibited refringent bile canaliculi-like structures, allowing to 
discriminate sinusoidal-like and canalicular-like membranes (Fig. 3A). Immunofluorescence 
labeling then revealed that various sinusoidal hepatic transporters such as OATP1B1, 
OATP2B1, OCT1 and MRP3 were expressed at the sinusoidal pole of monolayer-cultured 
human hepatocytes cells (Fig. 3B).  With respect to the canalicular ABC transporters 
MDR1/P-glycoprotein and MRP2, they were located to the rather wide bile canaliculi-like 
structures exhibited by cultured hepatocytes (Fig. 3B).  
 In order to determine whether sinusoidal transporters were active in monolayer-
cultured human hepatocytes, activities of NTCP, OATPs and OCT1 were then determined 
through measuring intracellular accumulation of reference substrates. As shown in Fig. 4, 
cultured human hepatocytes exhibited sodium-dependent taurocholate accumulation, thus 
indicating the presence of NTCP activity in these cells. In the same way, probenecid-
inhibitable accumulation of the OATP substrate E3S and verapamil-inhibitable accumulation 
of the OCT1 substrate TEA were clearly detected in cultured human hepatocytes (Fig. 5), thus 
reflecting OATP and OCT1 activity in such cells.   
 To finally investigate whether bile canaliculi-like  structures were functional in 
monolayer-cultured human hepatocytes, canalicular secretions of taurocholate, a substrate for 
BSEP (Stieger, 2011), of rhodamine 123, a substrate for MDR1/P-glycoprotein (Drenou et al., 
1993) and of CF, a substrate for MRP2 (Ellis et al., 2014; Laupeze et al., 2001) were analyzed 
and quantified using the BEI approach based on Ca2+ withdrawal-mediated disruption of 
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canaliculi (Liu et al., 1999b). Cultured human hepatocytes pre-incubated in Ca2+-free 
conditions exhibited decreased retention of taurocholate, rhodamine 123 and CF, 
comparatively to counterparts maintained in the presence of Ca2+ (Fig. 5). This demonstrates 
that monolayer-cultured human hepatocytes secreted taurocholate, rhodamine 123 and CF in 
bile canaliculi-like structures, allowing to calculate BEI values (55.1 %, 22.1 % and 10.9 % 
for taurocholate, CF and rhodamine 123).   
 
4. Discussion 
 The data reported in the present study demonstrate that human hepatocytes cultured in 
a standard monolayer configuration exhibit polarized expression of various sinusoidal and 
canalicular drug transporters, associated to detectable sinusoidal drug transporter activities 
and to the presence of functional bile canaliculi-like structures. Such data highlight the 
relative similarity to the in vivo situation of these human hepatocyte cultures and, 
consequently, their potential interest for hepatic drug transport studies.   
 This conclusion is also supported by the fact that most of sinusoidal and canalicular 
transporters were expressed at notable mRNA levels in monolayer-cultured human 
hepatocytes, even if, for some of them such as OATPs and OAT2, mRNA expression was 
rather decreased when compared to levels found in freshly isolated hepatocytes. The global 
expression of main hepatic drug transporters at the mRNA level, associated to detectable 
activities of NTCP, OATPs and OCT1, was moreover observed in human hepatocytes 
maintained in primary culture for 8-10 days, which fully agrees with the conclusion that 
monolayer-cultured human hepatocytes retain notable levels of drug transporter activity and 
protein expression with time in culture (Jigorel et al., 2005; Schaefer et al., 2012). By 
contrast, drug transporter expression, especially that of sinusoidal SLC transporters, is rapidly 
altered during primary culture for rodent hepatocytes, whatever the culture conditions 
  
13 
 
(Luttringer et al., 2002; Noel et al., 2013; Tchaparian et al., 2011), which has been 
hypothesized to reflect the in vitro acquisition of a cholestatic phenotype (Wilson et al., 
2014). NTCP expression, assessed by LC/MS-MS, as well as taurocholate and rosuvastatin 
uptake are thus reduced in sandwich-cultured rat hepatocytes with culture time, but are well 
maintained in human counterparts (Kotani et al., 2011; Qiu et al., 2013).This highlights inter-
species discrepancies with respect to expression of highly-differentiated hepatocyte markers 
such as drug transporters in primary hepatocytes. Similarly, expression of other liver-specific 
markers such as drug-metabolizing cytochromes P-450 has been shown to be better preserved 
in cultured human hepatocytes (Morel et al., 1990), which is fully consistent with the 
conclusion that primary human hepatocytes are phenotypically more stable than rodent 
counterparts (Guillouzo, 1998).  
 It is however noteworthy that some differences between freshly isolated human 
hepatocytes and monolayer-cultured counterparts with respect to transporter mRNA 
expressions exist and have to be kept in mind when using primary human hepatocytes for 
drug transport studies. It is notably the case for the sinusoidal transporter OATP1B3, whose 
expression is markedly reduced in monolayer-cultured human hepatocytes. Uptake of 
OATP1B3 specific substrates such as some digitalis-like compounds (Gozalpour et al., 2014) 
may therefore be under-estimated when using monolayer-cultured human hepatocytes for 
investigating kinetic features of hepatobiliary disposition of these compounds. The sinusoidal 
efflux orphan transporter MRP6, involved in the autosomal recessive metabolic disease 
pseudoxanthoma elasticum (Pahlman et al., 1984), is, by contrast, markedly up-regulated in 
monolayer-cultured human hepatocytes compared to freshly isolated counterparts. Transport 
of drugs putatively handled by MRP6 and that remain to be unambiguously identified, may 
consequently be over-estimated with the use of primary human hepatocytes. Other ABC 
transporters such as MDR1, MRP4 and MRP5 were also induced in monolayer-cultured 
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human hepatocytes, even if they remained among the less expressed drug transporters (Fig. 
3); these efflux transporters have similarly been found to be induced in primary mouse 
hepatocytes and in well-differentiated hepatoma HepaRG cells when compared to freshly 
isolated hepatocytes (Le Vee et al., 2013; Noel et al., 2013); such up-regulations can therefore 
be interpreted as a key hall-mark of hepatocytes when placed in an in vitro environment. 
 Primary human hepatocytes used in the present study were cultured in a monolayer 
configuration, i.e., they were seeded on plastic dishes without subsequent addition of a 
collagen or matrigel overlayer. Culturing hepatocytes in sandwich configuration, which is 
thought to represent the gold standard for drug transport studies with hepatocytes (Bi et al., 
2012; Swift et al., 2010), seems therefore to be not an absolute requirement for getting 
polarized hepatocytes, at least for human hepatocytes. This assertion is interestingly supported 
by the fact that calcium-sensitive efflux of taurocholate has been previously reported in 
collagen monolayer-cultured human hepatocytes (Kostrubsky et al., 2003), which likely 
suggests the presence of functional bile canaliculi-like structures in such cells. Moreover, no 
relevant difference for sinusoidal and canalicular drug transporter protein levels between 
sandwich- and monolayer-cultured human hepatocytes has been recently demonstrated though 
LC/MS-MS-based absolute quantification of transporters (Schaefer et al., 2012). Finally, 
highly-differentiated human hepatoma HepaRG cells exhibit polarized location of main drug 
transporters associated to taurocholate canalicular secretion, without being cultured in a 
sandwich configuration (Le Vee et al., 2013; Sharanek et al., 2014). Interestingly, a shared 
component between the culture medium used for our primary human hepatocytes and that 
used for HepaRG cells is DMSO, which is well known to favor hepatocyte survival and 
differentiation  (Choi et al., 2009; Isom et al., 1985; Noel et al., 2013) and to increase Ntcp 
and Oatp activity in primary rat hepatocytes (Jigorel et al., 2005). The way by which DMSO 
may promote polarized in vitro expression of drug transporters remains nevertheless to be 
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determined. It can be hypothesized that DMSO may induce formation and secretion of 
extracellular matrix components in primary cultures of hepatocytes, which may mimic the 
addition of a collagen or matrigel overlay. To clarify the exact role played by DMSO, 
additional studies comparing cultured human hepatocytes maintained in the presence or 
absence of this solvent are however likely required. Otherwise, it is noteworthy that 
monolayer hepatocyte cultures used in the present study were nearly confluent. This 
parameter has probably to be taken into account owing to the well-established influence of 
cell density on differentiated functions of cultured hepatocytes (Greuet et al., 1997).  
 The canalicular transporters BSEP, MRP2 and MDR1/P-glycoprotein were 
demonstrated to be functional in our primary human hepatocyte cultures, as demonstrated by 
the secretion of taurocholate, CF and rhodamine 123 into bile canaliculi-like structures, thus 
allowing to calculate BEI values, in a way similar to that used for sandwich-cultured 
hepatocytes. The BEI values for taurocholate (BEI=55.1 %) and CF (BEI=22.1 %) in 
monolayer-cultured human hepatocytes were however substantially lower than those 
previously reported in sandwich-cultured human counterparts (BEI around 70-75 % and 
BEI=34.0%, for taurocholate and CF, respectively) (Hoffmaster et al., 2004; Marion et al., 
2007), which may indicate higher activity of BSEP and MRP2 in hepatocytes maintained in a 
three-dimensional configuration. With respect to rhodamine 123, the BEI value found in our 
human hepatocyte cultures (BEI=10.9 %) was low, knowing however that rather low BEI 
values (BEI around 10-20 %) have also been reported for rhodamine 123 in sandwich-
cultured rat and mouse hepatocytes (Annaert et al., 2001; Noel et al., 2013). Additional 
studies are likely required to carefully and more extensively compare BEI values for drugs in 
monolayer- and sandwich-cultured human hepatocytes.   
 In summary, primary human hepatocytes maintained in a monolayer configuration 
were found to exhibit a polarized location of various major sinusoidal and canalicular drug 
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transporters, associated with efficient canalicular secretion of ABC transporter substrates and 
detectable sinusoidal drug transporter activities. Monolayer-cultured human hepatocytes have 
otherwise been demonstrated to retain signaling ways involved in transporter regulation 
(Jigorel et al., 2006). Taken together, these data indicate that primary human hepatocytes 
cultured in a monolayer dimension may likely represent a valuable in vitro model for studying 
activity and regulation of drug transporters. 
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Legends to figures 
 
Fig. 1. Sinusoidal drug transporter mRNA expression in monolayer-cultured human 
hepatocytes. 
Relative expression of sinusoidal drug transporters was determined in primary human 
hepatocytes  cultivated in a monolayer configuration (cPHH) and in freshly isolated primary 
human hepatocytes (fiPHH) by RT-qPCR, as described in Materials and Methods. Data are 
expressed in arbitrary units relatively to 18S RNA and are the means + SEM of at least 8 
independent hepatocyte populations. Transporter expressions in cPHH expressed as % of 
those found in fiPHH (arbitrarily set at 100 %) are indicated by numbers in brackets.*, p<0.05 
(Student’s t-test). 
Fig. 2. Canalicular drug transporter mRNA expression in monolayer-cultured human 
hepatocytes. 
Relative expression of canalicular drug transporters was determined in primary human 
hepatocytes cultivated in a monolayer configuration (cPHH) and in freshly isolated primary 
human hepatocytes (fiPHH) by RT-qPCR, as described in Materials and Methods. Data are 
expressed in arbitrary units relatively to 18S RNA and are the means + SEM of at least 8 
independent hepatocyte populations. Transporter expressions in cPHH expressed as % of 
those found in fiPHH (arbitrarily set at 100 %) are indicated by numbers in brackets.*, p<0.05 
(Student’s t-test). 
Fig. 3. Drug transporter localization in monolayer-cultured human hepatocytes. 
(A) Monolayer-cultured human hepatocytes morphology was examined by light phase 
contrast microscopy; bile canaliculi (BC), sinusoidal-like (SMb) and canalicular-like (CMb) 
membranes are indicated by black arrows. Bar = 15 µM. (B) Immunolocalization of 
sinusoidal and canalicular drug transporters was performed as described in Materials and 
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Methods. Pictures correspond to single immunolabeling, knowing that membrane transporter-
related fluorescence is green; blue fluorescence corresponds to 4,6-diamidino-2-phenylindole-
stained nuclei. Data shown are representative of four independent experiments. Transporter-
related membrane staining is indicated by white arrows. White stars indicate high background 
autofluorescence, most likely due to dead cells. Bar = 10 µM. 
Fig. 4. Sinusoidal drug influx activities in monolayer-cultured human hepatocytes. 
Cultured human hepatocytes were incubated with the NTCP substrate taurocholate (43.4 nM), 
the OATP substrate E3S (3.4 nM) or the OCT1 substrate TEA (40 µM) for 10 min, in the 
presence or absence of sodium (for taurocholate), 2 mM probenecid (for E3S) or 50 µM 
verapamil (for TEA). Intracellular accumulations of substrates were then determined by 
scintillation counting. Data are the means ± SEM of five (Taurocholate and TEA) or eight 
(E3S) independent experiments. *, p < 0.05 when compared to uptake in the presence of 
sodium (for taurocholate) or in the absence of inhibitors (for E3S and TEA) (Student’s t-test). 
Fig. 5. Canalicular drug transport activity in monolayer-cultured human hepatocytes. 
Canalicular secretions of the BSEP substrate taurocholate, the MRP2 substrate CF and the 
MDR1/P-glycoprotein substrate rhodamine 123 were determined as described in Material and 
Methods. Data are the means + SEM of nine (Taurocholate), seven (CF) or four (Rhodamine 
123) independent experiments, each being performed in triplicate. BEI values are indicated on 
the top of each graph. *, p<0.05 (Student’s t-test). FAU, fluorescence arbitrary unit. 
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Table 1. Categorization of drug transporter mRNA expression in freshly isolated primary 
human hepatocytes (fiPHH) and primary human hepatocytes cultivated in a monolayer 
configuration (cPHH). 
___________________________________________________________________________ 
Drug transporter           fiPHH          cPHH 
__________________________________________________________________________ 
 
NTCP       ++    ++ 
OATP1B1      ++    ++ 
OATP1B3      ++     + 
OATP2B1      ++    ++ 
OAT2       ++    ++ 
OCT1 +++  +++ 
MRP1       +/-    +/- 
MRP2       ++    ++ 
MRP3       ++    ++ 
MRP4       +/-    +/- 
MRP5       +/-    +/- 
MRP6  ++  +++ 
MDR1        +     + 
BSEP        +     + 
BCRP        +     + 
MATE1      ++    ++ 
___________________________________________________________________________ 
+++, very high expression (>100 units); ++, high expression (15-100 units); +, moderate 
expression (1-15 units); +/-, low expression (<1 unit). 
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Highlights 
 
- Monolayer-cultured human hepatocytes retain notable drug transporter mRNA expression 
- OATPs, OCT1 and MRP3 are detected at the sinusoidal pole of cultured hepatocytes  
- P-glycoprotein and MRP2 are expressed at the canalicular pole of cultured hepatocytes 
- Uptake transport is maintained in long-term monolayer-cultured human hepatocytes 
- Canalicular secretion is maintained in 10 day monolayer-cultured human hepatocytes 
 
 
